Search company, investor...

Founded Year

1993

Stage

Acq - Fin - IV | Alive

About Unither Pharmaceuticals

Unither Pharmaceuticals manufactures and distributes pharmaceutical products. It offers a range of sterile unit dose drugs in liquid, powder, and effervescent forms, drug delivery systems, and dry formulations. The company's products include blow-fill-seal, liquid stick-packs, powder stick-packs, tablets, pharmaceutical bottles, suppositories, and pessaries. The compay was founded in 1993 and is based in Amiens, France.

Headquarters Location

151 Rue Andre Durouchez CS 28028

Amiens, 80084,

France

+33 (0)3 22 54 73 00

Loading...

Loading...

Unither Pharmaceuticals Patents

Unither Pharmaceuticals has filed 8 patents.

The 3 most popular patent topics include:

  • amines
  • beta blockers
  • diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/28/2018

4/4/2023

Analgesics, Dosage forms, Prodrugs, Phenols, Amines

Grant

Application Date

2/28/2018

Grant Date

4/4/2023

Title

Related Topics

Analgesics, Dosage forms, Prodrugs, Phenols, Amines

Status

Grant

Latest Unither Pharmaceuticals News

Blow Fill Seal Technology Market Anticipated to US$ 6,206.5 Million by 2033: Exclusive Research Report by Future Market Insights, Inc.

Dec 11, 2023

Valley Cottage, New York, UNITED STATES NEWARK, Del, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The projected trajectory of the global blow fill seal technology market foresees an estimated value of US$ 3,246.7 million in 2023, poised to surge to an impressive US$ 6,206.5 million by 2033. This upward trend signifies a robust sales revenue expansion, anticipating a notable CAGR of 6.8% throughout the forecast period. The burgeoning pharmaceutical industry, coupled with manufacturers increasingly embracing advanced sterilization technologies like blow fill seal (BFS), is set to propel the global market forward. The adoption of BFS addresses concerns related to human intervention and mitigates the risks of drug contamination during the filling and packaging processes. This technology presents a myriad of advantages, including packaging flexibility, reduced operating costs, high-level sterility assurance, minimal space and component inventory requirements, as well as a limited workforce necessity. These attributes collectively position BFS as an ideal technology for pharmaceutical companies engaged in drug packaging applications. Get an Exclusive Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4407 The latest generation of aseptic blow-fill-seal technology machines is specifically dedicated to a whole new range of adapted insertion applications. These modular insertion isolators are typically located outside the categorized machine room, separate from but directly connected to the B/F/S unit through a transfer tunnel. The isolator and tunnel are typically sterilized with vaporized hydrogen peroxide, and the Class 100 environment within it is maintained by HEPA filtration. This new addition to the aseptic B/F/S system has not only streamlined the insertion process but has also provided a higher level of sterility assurance for products with tips-and-caps and rubber/silicone stoppers inserted under aseptic conditions. This technology was introduced by Rommelag, incorporating insertion with blow-fill-seal, resulting in an advanced blow-fill-insert-seal technology. During the insertion process, either a preservative-free multi-dose system or a micro-brittle applicator could be inserted according to the requirements. Outline of Important Trends Shaping the Global Blow Fill Seal Technology Market Regenerative LDPE in BFS Containers Enhances Sustainability, Cost-Efficiency, and Performance for Pharmaceutical Packaging The use of Regenerative LDPE (rLDPE) as a raw material for blow-fill-seal (BFS) containers is a growing trend driven by factors such as sustainability, cost-effectiveness, performance, regulatory compliance, and consumer demand. BFS companies are finding that rLDPE is a viable and sustainable alternative to virgin LDPE, offering similar performance characteristics at a lower cost. Moreover, the use of rLDPE can contribute to sustainability goals by reducing reliance on virgin plastic and extending the shelf life of products. Numerous organizations across the pharmaceutical and healthcare industry are actively utilizing regenerative LDPE (rLDPE) in the production of blow-fill-seal (BFS) containers. These organizations recognize the advantages of rLDPE in terms of sustainability, cost-effectiveness, and performance, making it an attractive choice for packaging sterile and single-dose pharmaceutical products. For instance, key players such as Silgan Unicep, Ritedose Corporation, and Amanta Healthcare have incorporated rLDPE into their BFS manufacturing process. Additionally, Unither Pharmaceuticals SAS utilized around 1,117 kg/ton of rLDPE at its Gannat production site, successfully reducing emissions by over 60%. “Unit dosage packaging, such as prefilled syringes, is in high demand. This, in turn, is spurring the demand for blow-fill-seal technology in the global market. In response to this market dynamic, pharmaceutical companies are strategically integrating BFS technology into their manufacturing processes to meet the escalating demand for unit dose packaging.”- Says Ismail Sutaria , Principal Consultant of packaging and Materials at Future Market Insights. Key Takeaways from the Global Blow Fill Seal Technology Market Prefilled syringes and injectable lead the global BFS technology market, capturing half of the value share and are anticipated to increase by 340 BPS points during the forecast period. Ampoules are growing at a CAGR of 6.4% and are expected to gain 1/5th of the market share by the end of 2033. Bottles will gain incremental opportunities worth USD 507.8 million by the end of the forecast years. Polyethylene is dominating the market, gaining more than 61% of the market share in 2023, creating an incremental growth opportunity of USD 2,013.4 million by the end of 2033. Polypropylene is anticipated to record 6.5% during 2023-2033, with an expansion rate of 1.9 times its current market value. The pharmaceutical industry is the prominent user of BFS technology, with 97% of the market share driven by rapid expansion. In the pharmaceutical industry, respiratory is anticipated to generate 1,202.4 million incremental growth opportunities during the forecast years. Food and beverage are expected to expand 1.8 times its current market value in the upcoming years. Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.futuremarketinsights.com/checkout/4407 Global Blow Fill Seal Technology Market Landscape Unither Pharmaceuticals SAS, Rommelag SE & Co. KG, Woodstock Sterile Solutions, Curida AS, New Vision Pharmaceuticals LLC, Weiler Engineering Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Nephron Pharmaceuticals Corporation, Horizon Pharmaceuticals Inc, are some of the noticeable players in the market. The tier 1 players in the market hold 10–15% of the overall blow fill seal technology market including GlaxoSmithKline plc, Takeda Pharmaceuticals International AG, and Horizon Pharmaceuticals Plc. Providing Specialized Services in the BFS Technology Industry Manufacturers can go beyond their product offerings and provide value-added services to enhance customer satisfaction and expand revenue streams. Several key players, such as Rommelag SE & Co. KG, Woodstock Sterile Solutions, and Weiler Engineering Inc., already offer a wide range of value-added services along with their portfolios. For instance, Weiler Engineering is involved in the provision of research and development services, which include special mold and filling development, and 3D printing, among others. Additionally, Rommelag also offers a variety of value-added service solutions, including pharmaceutical qualification and validation, after-sales services, and machine modernization services. Following similar trends, manufacturers can provide expert advice on BFS container design, material selection, and compatibility with specific products to help customers optimize their packaging solutions and meet regulatory requirements. They can also offer sustainability consulting services, and implementing recycling programs can help customers reduce their environmental impact and meet sustainability goals. Manufacturers can collaborate with customers to develop and customize BFS containers for specific product requirements. This will strengthen customer relationships and differentiate the manufacturer's offerings. Since there is a lack of skilled labor in certain regions, providing training and education programs to customers' staff on BFS container handling, filling procedures, and quality control measures can enhance their expertise and ensure proper product handling. Key Developments In December 2021, Woodstock secured a United States patent for their cold blow fill seal system. This innovative approach involves meticulous temperature control to prevent heat-related damage. It is particularly suitable for medications susceptible to temperature-induced degradation. In January 2021, Berry Global Healthcare introduced Cyrano, their latest blow-fill-seal closure, renowned for its lightweight design. Tailored to minimize plastic usage, Cyrano serves as an accessible solution for various intravenous and infusion systems. Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-4407

Unither Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Unither Pharmaceuticals founded?

    Unither Pharmaceuticals was founded in 1993.

  • Where is Unither Pharmaceuticals's headquarters?

    Unither Pharmaceuticals's headquarters is located at 151 Rue Andre Durouchez, Amiens.

  • What is Unither Pharmaceuticals's latest funding round?

    Unither Pharmaceuticals's latest funding round is Acq - Fin - IV.

  • Who are the investors of Unither Pharmaceuticals?

    Investors of Unither Pharmaceuticals include Parquest Capital, Keensight Capital, IK Partners, Eric Goupil, GIC and 6 more.

  • Who are Unither Pharmaceuticals's competitors?

    Competitors of Unither Pharmaceuticals include Alpex Pharma, Cellworks, Intas Pharmaceuticals, Prevtec Microbia, Adello Biologics and 7 more.

Loading...

Compare Unither Pharmaceuticals to Competitors

P
Perpetual Pharmaceuticals

Perpetual Pharmaceutical is engaged in the development of an insulin-based medication called Briodurance that senses when blood glucose levels are on the rise

A
Axis Pharmaceutical Packaging

Axis Pharmaceutical Packaging has developed a high-quality, high-speed, pharmaceutical solid dose medication bottle filling machine that meets industry and FDA standards.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

S
Savior Lifetec

Savior Lifetec develops specialty injectable medicines and drugs. Its products and solutions include carbapenem generics, injection generics, controlled-release generics, the development of new dosage forms and drugs, and the active pharmaceutical ingredient (APIs), excipients, intermediates, and dosage forms of the aforementioned products. The company was founded in 2004 and is based in Taiwan.

V
Vaxent

Vaxent has developed a StepNovA vaccine for Group A streptococcus

O
OcuNexus Therapeutics

OcuNexus Therapeutics is a clinical-stage company focused on the healthcare sector, specifically in the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 Hemichannel, which is responsible for inflammasome mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.